Q32 Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-60.61	-53.74	-42.81	-37.56
Depreciation & Amortization	0.49	0.5	0.37	0.05
Other Amortization	0.18	0.09	0.1	0.1
Loss (Gain) From Sale of Assets	-	-	0.02	-
Stock-Based Compensation	3.66	1.43	1.24	0.75
Other Operating Activities	-16.52	6.74	3.18	-
Change in Accounts Payable	-1.14	2.03	-1.24	1.1
Change in Unearned Revenue	-40.34	-25.85	25.85	-
Change in Other Net Operating Assets	45.2	50.13	2.34	2.58
Operating Cash Flow	-67	-18.68	-10.96	-32.98
Capital Expenditures	-0.07	-0.01	-2.49	-0.16
Sale of Property, Plant & Equipment	-	-	0.02	-
Investing Cash Flow	19.93	-0.01	-2.47	-0.16
Long-Term Debt Issued	-	5.5	30	-
Long-Term Debt Repaid	-	-5.2	-	-
Net Debt Issued (Repaid)	51.44	0.3	30	-
Issuance of Common Stock	43.45	0.11	0.07	0.12
Financing Cash Flow	94.9	0.41	30.07	20.11
Net Cash Flow	47.82	-18.28	16.65	-13.03
Free Cash Flow	-67.07	-18.68	-13.44	-33.14
Free Cash Flow Margin	-	-	-202.10%	-
Free Cash Flow Per Share	-5.06	-2.58	-1.91	-5.12
Levered Free Cash Flow	-71.27	-40.9	-8.73	-
Unlevered Free Cash Flow	-70.63	-40.67	-8.83	-
Change in Net Working Capital	26.34	12.44	-16.57	-

Source: S&P Capital IQ. Standard template. Financial Sources.